Drug profile · INN
entecavir
ENTAC
entecavir (ENTAC) is a dna polymerase/reverse transcriptase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — entecavir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 3
- Programs
- 23
- Data quality
- 0.89
Quick answer
entecavir (ENTAC) is a dna polymerase/reverse transcriptase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA polymerase/reverse transcriptase inhibitor
Primary target: DNA polymerase/reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is entecavir?
entecavir (ENTAC) is a dna polymerase/reverse transcriptase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for entecavir?
ENTAC is a marketed brand name for entecavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of entecavir?
entecavir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.